Citadel Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-2,567
| Closed | -$25K | – | 8237 |
|
|
2016
Q3 | $25K | Sell |
2,567
-666
| -21% | -$4.72K | ﹤0.01% | 6999 |
|
|
2016
Q2 | $18K | Buy |
3,233
+766
| +31% | +$5.2K | ﹤0.01% | 6659 |
|
|
2016
Q1 | $19K | Buy |
2,467
+600
| +32% | +$4.62K | ﹤0.01% | 6485 |
|
|
2015
Q4 | $25K | Buy |
1,867
+1,200
| +180% | +$20.7K | ﹤0.01% | 7792 |
|
|
2015
Q3 | $11K | Buy |
667
+234
| +54% | +$4.8K | ﹤0.01% | 8444 |
|
|
2015
Q2 | $10K | Buy |
+433
| New | +$6.85K | ﹤0.01% | 8415 |
|
|
2015
Q1 | – | Sell |
-1,667
| Closed | -$19K | – | 9053 |
|
|
2014
Q4 | $19K | Buy |
+1,667
| New | +$18.1K | ﹤0.01% | 7868 |
|
|
2014
Q3 | – | Sell |
-733
| Closed | -$14K | – | 8628 |
|
|
2014
Q2 | $14K | Sell |
733
-200
| -21% | -$3.53K | ﹤0.01% | 7475 |
|
|
2014
Q1 | $17K | Sell |
933
-184
| -16% | -$3.02K | ﹤0.01% | 7366 |
|
|
2013
Q4 | $12K | Sell |
1,117
-850
| -43% | -$9.5K | ﹤0.01% | 6675 |
|
|
2013
Q3 | $24K | Sell |
1,967
-2,400
| -55% | -$25.3K | ﹤0.01% | 6133 |
|
|
2013
Q2 | $41K | Buy |
+4,367
| New | +$56.1K | ﹤0.01% | 5766 |
|
Citadel Advisors's CASC Position: Q1 2018 in Review
Citadel Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 10,792 shares — an estimated $40K sold.
Citadel Advisors first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $523K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Citadel Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Citadel Advisors sold 10,792 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $40K.
- Citadel Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Cascadian Therapeutics, Inc. position peaked at $523K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.